Neuropathy affects over 30‰ of the people with advanced HIV disease. There is a need for effective neuropathy treatments that focus on reparative mechanisms while alleviating pain.

This study looks at the pain reduction, safety, tolerability and pharmacokinetics (amount of drug in recipient’s blood) of prosaptide versus placebo. In addition, the study will determine whether prosaptide has sensory reparative properties, as determined by neurological examinations, including nerve conduction studies conducted on site.

 

Volunteers will be randomly assigned to one of four dosing groups. Volunteers must be willing to stop their current neuropathy treatment for the duration of the study, and they will be compensated up to $50 per visit.

No volunteer will receive placebo.

 

• HIV+ adult male or female
• Diagnosis of painful HIV-associated neuropathy in both feet
• Currently using ddI, d4T or ddC > 4 months OR not currently using ddI, d4T or ddC

Enrolling
--

This ad was reviewed and approved by the AIDS ReSearch Alliance Institutional Review Board in October, 2003.